Primary prophylaxis implementation and long‐term joint outcomes in Swedish haemophilia A patients

Alexandros Arvanitakis,Caroline Jepsen,Nadine G Andersson,Fariba Baghaei,Jan Astermark
DOI: https://doi.org/10.1111/hae.15013
2024-04-06
Haemophilia
Abstract:Introduction Primary prophylaxis is the gold standard in severe haemophilia A (SHA) but time to escalate the prophylaxis regimen varies. Aim Assess prophylaxis implementation and long‐term joint health outcomes in SHA with primary prophylaxis. Methods Adult male patients born after 1980, with SHA on primary prophylaxis, started before the age of 3 years and second joint bleed, and no history of FVIII inhibitors, were enrolled. Repeated joint‐health examinations were performed with HJHS or HEAD‐US; VERITAS‐PRO assessed adherence. Results Thirty patients were enrolled with, at inclusion, median age 33.5 years, annualized bleed rate and joint bleed rate 0, and FVIII consumption 4232 IU/kg/year, respectively. The median age was 1.2 years, at prophylaxis start once weekly with a median FVIII dose of 47.7 IU/kg, and 1.7 years, by the time escalation to a final regimen had occurred, with a median infusion frequency of thrice weekly and FVIII dose 41.7 IU/kg, respectively. Older age correlated with later transition to escalated prophylaxis (p
hematology
What problem does this paper attempt to address?